Neuroblastoma is an extremely malignant solid tumor in children, characterized by spontaneous differentiation and regression. An epidermal growth factor-like homeotic protein, delta-like (dlk), has been involved in differentiation of neuroblastoma cell lines, but is unknown in in vivo expression of neuroblastoma. By using in situ hybridization and immunohistochemistry, dlk mRNA and protein expression were studied in formalinfixed archival tissues from 10 patients with neuroblastoma, five with ganglioneuroblastoma, and five with ganglioneuroma. Three adrenal tissues from children died of diseases other than adrenal tumors and one from an adult with pheochromocytoma were severed as normal and disease controls. The results showed strong immunoreactive dlk staining in endothelial cells in neuroblastoma, ganglioneuroblastoma and ganglioneuroma. Dlk was detectable in mature neuromatous stroma and gangliocytes of ganglioneuroma, but not in neuroblasts of neuroblastoma and ganglioneuroblastoma, neither in gangliocytes of ganglioneuroblastoma. In contrast, dlk mRNA expression was mainly observed in the gangliocytes, but was less intense in the neuroblasts and neuromatous stroma cells. Endothelial cells were essentially devoid of dlk mRNA expression. The findings indicated that there is differential expression of dlk gene and protein among neuroblastoma, ganglioneuroblastoma and ganglioneuroma. The stronger expression of dlk in gangliocytes in ganglioneuroma, in contrast to weaker or no expression in gangliocytes in ganglioneuroblastoma and neuroblasts in neuroblastoma, suggests upregulation of dlk during differentiation of neuroblastoma into more benign form. Furthermore, higher dlk protein expression in the tumor endothelium than in the endothelium of normal adrenal gland implies that dlk may regulate the endothelial function in neuroblastic tumors.
Neuroblastoma cells are derived from postganglionic sympathetic neuroblasts and frequently exhibit features of neuronal differentiation. Neuroblastic tumors have the unique ability to differentiate and mature, which delineates a family composed of neuroblastoma, ganglioneuroblastoma, and ganglioneuroma. Ganglioneuroma is the most benign form, consisting of gangliocytes and mature neuromatous stroma. Ganglioneuroblastoma is composed of both immature gangliocytes and differentiating neuroblasts and has intermediate malignant potential. Neuroblastoma is the most immature, undifferentiated, and malignant form, which may show spontaneous or induced differentiation to ganglioneuroblastoma or ganglioneuroma. The cause of trans-differentiation of one form into another is unknown, but probably involves pathways that signal the cell to differentiate. 1 Delta-like protein (dlk) is a member of the epidermal growth factor (EGF)-like family, which includes proteins such as Notch, Delta, and Serrate in the control of cell differentiation. 2 Structural analysis reveals that dlk contains six EGF-like repeats in the extracellular domains, and a short intracellular domain. 3 EGF-like proteins act as receptors or as ligands that participate in cell-tocell interactions in differentiation leading to a variety of mature tissues. 4, 5 Dlk can be expressed as a soluble or an integral transmembrane protein, which is released to the extracellular medium by the action of specific protease. The unique structure and expression pattern of dlk suggests that dlk may play a role in the development and differentiation of a variety of organs or cell types, 6, 7 including adipogenesis, [8] [9] [10] [11] [12] hematopoiesis [13] [14] [15] [16] and development of pancreas, 17, 18 placenta, 19, 20 and adrenal gland. 21, 22 Dlk is expressed in tumor cell lines with neuroendocrine features, including neuroblastoma, pheochromocytoma, and subsets of small cell lung carcinoma. 20, [23] [24] [25] [26] The expression of dlk seems to correlate with the maturation along the chromaffin lineages. 27 In this study, we characterized in vivo expression of dlk in neuroblastoma, ganglioneuroblastoma, and ganglioneuroma by using immunohistochemistry (IHC) and in situ hybridization (ISH) to bring further insights into the role of dlk in differentiation and neovascularization of neuroblastoma.
Materials and methods

Patients and Samples
Formalin-fixed, paraffin-embedded specimens of neuroblastoma, ganglioneuroblastoma, and ganglioneuroma accessioned between July 1991 and December 2002 were retrieved from the archives of the Department of Pathology, Chang Gung Memorial Hospital, Kaohsiung, Taiwan. All the patients were diagnosed before the age of 19 years. These patients were classified according to the International Neuroblastoma Staging System. 28 Histologic classification was according to the International Neuroblastoma Pathology Committee. 29 Based on the percentage and degree of differentiation of the neuroblastoma cells and the presence of gangliocytes, neuroblastic tumors were classified into neuroblastoma, ganglioneuroblastoma, and ganglioneuroma.
Immunohistochemistry
In all, 2-mm thick tumor sections on poly-L-lysinecoated slides were dewaxed, treated with 3% hydrogen peroxide for 10 min to inactivate the endogenous peroxidase activity and microwaved for 10 min in 10 mM citrate buffer to retrieve antigens. The sections were then incubated with goat anti-human dlk antibody (SC-8624, 1:50 dilution) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1 h at room temperature. After washing with PBS, the sections were reacted with the HRP/ Fab polymer conjugate (PicTuret-Plus kit, Zymed, South San Francisco, CA, USA) according to the manufacturer's instructions and then incubated with DAB chromogen. The sections were finally counter stained with Gill's hematoxylin (Merck, Darmstadt, Germany). To analyze whether dlk expression in endothelial proliferation indeed was related to neurotic tumors, three specimens of adrenal gland from autopsy infants without adrenal tumor were served as the negative control. One specimen from a case of pheochromocytoma was used as a positive control. The findings of dlk expression was arbitrarily graded into three categories depending on the percentage of the cells stained: (À), if less than 10% of cells were stained; ( þ ), if 10 to 50% of cells were stained; ( þ þ ), if 450% of cells were stained.
Nonradioactive ISH
To detect the localization of dlk mRNA in the tumor tissue, we used a nonradioactive ISH with catalyzed reporter deposition method for signal amplification as previously described. 30 For preparation of the probes, the dlk cDNA was obtained and the segment containing nucleotides 391-783 was subcloned into pGEM vector. Digoxigenin-labeled antisense riboprobes were synthesized using in vitro transcription method according to the manufacturer's instructions (Roche, Mannheim, Germany). The sense riboprobes were also synthesized by the same method to be served as the negative control in ISH. The cohort sections were prepared by cutting the paraffinembedded tissue blocks to 4 mm in thickness and placing on the silane coating slides followed by deparaffinization. The procedure of deparaffinizaion and rehydration of the sections was handled under RNAse-free condition with the use of diethylpyrocarbonate water. The sections were then digested with 20 mg/ml proteinase K at 371C for 25 min, followed by acetylation in freshly prepared 0.25% acetic anhydride in 0.1 M triethanolamine pH 8.0 for 10 min. The digoxigenin-labeled riboprobes were diluted in mRNA ISH solution (DAKO, Capinteria, CA, USA) to 1 mg/ml, denatured at 1001C and then added on the tissue section. The slides were placed in a humid chamber and incubated in an incubator at 501C overnight for hybridization.
After hybridization, the sections were washed to remove the unbound probes and incubated with rabbit HRP-anti-digoxigenin antibody (1:150) (DAKO) in blocking buffer for 1 h at room temperature, followed by wash to remove unbound antibody. The signals were amplified with DAKO GenPoint kit according to the manufacturer's protocol and finally developed by adding DAB.
Results
Clinicopathological characteristics of the patients were listed in Table 1 . There were 10 neuroblastoma, five ganglioneuroblastoma, and five ganglioneuroma. Nine are males and 11 females. The mean age at diagnosis was 2.5 years (range, 0-7 years) for patients with neuroblastoma, 1.3 years (range, 3 months-3.8 years) for ganglioneuroblastoma, and 11.6 years (range, 2.8-19 years) for ganglioneuroma. The locations of primary tumors were adrenal gland (six), mediastinum (eight), retroperitoneum (four), paraspinal (one), and others (one). The tumors were detected in eight patients in stage I, two in stage II, four in stage III, five in stage IV, and one in stage IVs according to the International Neuroblastoma Staging System.
The results of IHC were shown in Table 2 and Figure 1 . Dlk immunoreactivity was not detected in any neuroblastic cells of neuroblastoma and ganglioneuroblastoma and in immature gangliocytes of ganglioneuroblastoma, but was detected in both nuclei and cytoplasm of mature gangliocytes and neuromatous stroma of ganglioneuroma. Interestingly, the strong dlk immunoreactivity was present mainly in the cytoplasm of endothelial cells in 70% of neuroblastoma (7/10), 80% of ganglioneuroblastoma (4/5), and 80% of ganglioneuroma (4/5). We compared dlk expression in the neuroblastoma, ganglioneuroblastoma, and ganglioneuroma from adrenal glands of normal infants and from pheochromocytoma. IHC analysis showed that the endothelial cells of pheochromocytoma were also strongly stained for dlk, similar to that observed in our neuromatous tumors. Dlk was weakly stained in the endothelial cells of normal adrenal glands and was absent in the tumor cells of pheochromocytoma and in the medulla cells of normal adrenal glands.
By ISH, dlk mRNA expression was mainly observed in the gangliocytes of both ganglioneuroblastoma and ganglioneuroma, and was relatively weakly present in the neuroblastic cells and neuromatous stroma cells of neuroblastoma, ganglioneuroblastoma, and ganglioneuroma. The signals were detected in both the nuclei and cytoplasm, implying that dlk was produced in the gangliocytes, neuroblasts, and neuromatous stroma cells. However, the endothelial cells were essentially devoid of dlk mRNA expression in neuroblastoma, ganglioneuroblastoma, and rarely in ganglioneuroma ( Figure 2 ).
Discussion
In this study, immunoreactive dlk was detectable in mature neuromatous stroma and gangliocytes of ganglioneuroma, but not in neuroblasts of neuroblastoma, ganglioneuroblastoma, neither in gangliocytes of ganglioneuroblastoma. In addition, by ISH, dlk mRNA expression is mainly observed in the gangliocytes of both ganglioneuroma and ganglioneuroblastoma, but was less intense in the neuroblastic cells of neuroblastoma, ganglioneuroblastoma, and ganglioneuroma, as well in the neuromatous stroma in ganglioneuroma. The findings indicate that there is differential expression of dlk gene and protein among neuroblastoma, ganglioneuroblastoma, and ganglioneuroma. The stronger expression of dlk in gangliocytes in ganglioneuroma, in contrast to weaker or no expression in gangliocytes in ganglioneuroblastoma and neuro- 
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Dlk expression in neuroblastoma C-C Hsiao et al blasts in neuroblastoma, suggests upregulation of dlk during differentiation of neuroblastoma into more benign form.
Our findings also demonstrated that the expression of immunoreactive dlk was present mainly in the cytoplasm of endothelial cells in neuroblastoma, ganglioneuroblastoma, and ganglioneuroma, while dlk mRNA expression was not found in endothelial cells by ISH. In contrast to the distribution of dlk proteins, dlk mRNA was detected in both the cytoplasm and nuclei of neuroblastic cells and gangliocytes. The results may suggest that dlk proteins are actively produced by gangliocytes or neuroblastic cells and then transported to endothelium and neuromatous stroma. Or alternatively, lack of mRNA in nondividing endothelial cells may imply that mRNAs are short-lived and are not expressed like proteins, which are relatively more stable. However, both assumptions need further confirmation.
According to Huang et al, 31 dlk mRNA was present in hepatocytes of liver fibrosis with biliary atresia, but not in nonparenchymal cells that were strongly positive for dlk antibody in the immunohistochemical study. They suggested that dlk protein is mainly produced in hepatocytes in the liver but is transported to hepatic stellate cells via a paracrine route. This finding is consistent with ours in that dlk may act like a paracrine growth factor in regulation of endothelial function. Although the involvement of dlk in endothelial function and neovascularization remains to be elucidated, we have found an interesting dose-dependent promotion of cell proliferation and migration of human umbilical vein endothelial cells by adding the protein of the extracellular domain of dlk in vitro (unpublished data).
Dlk shows a high degree of homology with the EGF-like proteins of Drosophila and other invertebrates that are involved in the differentiation of different tissues and structures. 32 In the present study, dlk protein expression is positively correlated with differentiation in the tumor cells from the most immature form, that is, neuroblastoma to the most mature form, that is, ganglioneuroma. The low abundance of dlk expression in neuroblastic cells may imply downregulation of dlk in this specific population of tumor cells. These results also suggest that dlk expression may be required during the initial stages of neuroblastoma cell differentiation toward a mature phenotype.
Dlk plays an important role to trigger Notch activation and to switch between proliferation and differentiation into mature cells. 33, 34 Members of the Notch family attenuate the expression of proneural genes and may promote differentiation into neuronal cells. Gaetano et al studied the differentiation of primitive neuroblastoma cell lines and found that treatment with dbcAMP, an agent that induces differentiation of the chromaffin phenotype, increased the expression of dlk. Such increment in dlk expression could be inhibited by treatment with retinoic acid, which induces a neuronal phenotype. 35, 36 Our data coincide with these in vitro findings and demonstrate that elevated dlk expression favors the tendency toward differentiation. In conclusion, the results of this in vivo study indicate that dlk is involved in the differentiation and the endothelial function of neuroblastic tumors. The precise mechanism or mode of action of dlk in this special kind of tumor is unknown.
